TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering 19 studies and nearly 16 million participants found ADHD was associated with higher all-cause mortality and higher risks of suicide, injury and natural-cause death. ADHD medication use was associated with lower all-cause mortality in a separate analysis of only three studies; the authors cautioned that this finding may reflect differences between treated and untreated people.
A systematic review and meta-analysis of research involving nearly 16 million people found that ADHD was associated with higher all-cause mortality, as well as higher risks of suicide, injury and natural-cause death. The study also found lower mortality associated with ADHD medication use, but that result came from only three studies and does not establish that medication caused the difference.
Researchers led by Joshua Stott, PhD, of University College London, analyzed 19 studies with 15,920,970 participants, most of whom were male. Twelve studies contributed data to five meta-analyses. The review, published in JAMA Network Open, included peer-reviewed research available through July 2025 and used a range of ways to identify ADHD, including diagnostic criteria, self-identification, trait measures and genetic risk scores.
For all-cause mortality, nine studies produced a pooled hazard ratio of 1.71 for people with ADHD compared with people without ADHD (95% confidence interval 1.31–2.24). The researchers also reported higher risks of death by suicide (hazard ratio 1.89), unintentional or intentional injury (1.55), and natural causes (1.27). These are relative estimates from the included studies, not a prediction of an individual’s absolute risk or lifespan.
In a separate analysis of three studies, ADHD medication use was associated with a lower all-cause mortality rate (hazard ratio 0.75, 95% confidence interval 0.64–0.87). The authors said this result should be interpreted cautiously: treated and untreated groups may differ in healthcare access, socioeconomic circumstances, illness severity, treatment adherence and coexisting psychiatric conditions. The analysis cannot show that medication itself reduced deaths.
Mortality Findings Point to Care Gaps
The findings add evidence that people identified as having ADHD face elevated mortality risks across several causes of death. They matter for clinicians and public health services because some of the pathways discussed by the researchers may involve factors that can be addressed through appropriate care and support. The results do not mean that an individual with ADHD will die early, nor do they establish that ADHD alone accounts for the differences.
Stott and colleagues described possible pathways including impulsivity, emotional dysregulation and risk-taking in relation to injuries, and co-occurring conditions such as depression in relation to suicide. They also pointed to smoking, alcohol use, barriers to healthcare, cardiovascular disease and metabolic disorders as possible contributors to natural-cause mortality. These are proposed explanations, not mechanisms proven by this review.
The medication finding may draw attention because it suggests a possible connection between treatment and lower mortality. But with only three studies, and potential differences between people who do and do not receive treatment, it is not evidence that ADHD medication prevents death. The authors’ emphasis was on access to accurate diagnosis and treatment, while recognizing that the review cannot determine which interventions would change mortality outcomes.
As an affiliate, we earn on qualifying purchases.
How the Review Expanded Earlier Research
Earlier studies had also reported higher mortality among people with ADHD. Some had suggested a six- to seven-year life-expectancy gap, but that estimate comes from prior research and should not be treated as a conclusion about every person with ADHD. The new review combined findings across populations and examined both all-cause and cause-specific mortality.
The included studies differed in their settings and methods. The researchers reported substantial statistical heterogeneity in the analyses of all-cause mortality, suicide and injury; the natural-cause analysis did not show the same level. They said the studies consistently pointed toward higher mortality in ADHD groups, while the size of the association varied. Differences in diagnostic criteria and access to care across countries, along with gender imbalances in many studies, were among the limitations noted.
In U.S. figures cited in the report, the CDC estimates that 15 million adults—about 6%—have ADHD, and nearly one in three take stimulant medication. The agency also estimates that 7 million children ages 3 to 17 have an ADHD diagnosis. Those figures describe U.S. diagnoses and medication use; they are not estimates produced by the mortality meta-analysis.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, study lead, speaking to MedPage Today
As an affiliate, we earn on qualifying purchases.
What the Associations Cannot Establish
The analysis cannot establish that ADHD causes higher mortality, identify how much risk is attributable to ADHD itself, or predict outcomes for any one person. The studies used differing methods to define ADHD and were conducted across varied populations, and the review found heterogeneity in several cause-specific analyses.
The apparent association between medication use and lower mortality is especially uncertain. It was based on only three studies and may be affected by confounding, including differences in healthcare access, health status and other characteristics between treated and untreated people. The report does not show whether a specific medication, dose or duration changes mortality risk, or whether the association would persist after accounting for those differences.
The review also does not determine which prevention or care measures would reduce deaths, or explain the precise contribution of co-occurring conditions and social factors. Its findings describe patterns across research studies, not a direct test of interventions.
As an affiliate, we earn on qualifying purchases.
Further Research on Treatment and Risk
The study reports results from research available through July 2025; the article does not describe a planned follow-up study or a specific next milestone. Further research would need to test the medication association in larger, better-controlled datasets and account for differences in health, treatment access and psychiatric conditions. More consistent measures of ADHD and broader representation across age groups and genders could also help clarify how widely the estimates apply.
For now, the findings are best read as evidence of an association that supports attention to diagnosis and healthcare access, not as proof that medication prevents death or that every person with ADHD faces the same risk. The researchers’ report calls attention to population-level patterns while leaving the causes and most effective responses unresolved.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the study find about ADHD and mortality?
Across the included studies, ADHD was associated with higher all-cause mortality and higher reported risks of suicide, injury and natural-cause death. These are relative associations, not an individual prediction.
Does the study show that ADHD causes early death?
No. The review combined observational research and found associations; it cannot establish that ADHD itself caused the differences or determine an individual’s life expectancy.
Does the medication result prove ADHD treatment lowers mortality?
No. Medication use was associated with lower all-cause mortality in an analysis of three studies, but the authors warned that differences between treated and untreated groups may explain some or all of the association.
What factors might contribute to the higher risks?
The researchers discussed possible roles for injury-related risk-taking, co-occurring depression, smoking, alcohol use, barriers to healthcare, and cardiovascular or metabolic conditions. The review did not prove these factors caused the observed mortality patterns.
How many people were included in the review?
The review included 19 studies and 15,920,970 participants. Twelve studies provided outcomes used in the meta-analyses.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
